4540.T
TSUMURA & CO.
プライム · 医薬品 · 医薬品 · JP
JPY 3,751.00
−0.77%Year over year
Reported trailing growth
- Revenue
- +6.4%
- EBITDA
- —
- EBIT
- -12.2%
- EPS
- -12.0%
- Free cash flow
- —
- Operating cash flow
- -26.9%
Forward estimates
Based on analyst estimates
- Revenue
- +2.8%
- EBITDA
- —
- EPS
- -14.8%
Three-year CAGR
- Revenue
- +11.2%
- EBITDA
- +15.3%
- EBIT
- +19.0%
- Net income
- +19.5%
- EPS
- +20.4%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026